Organon Q4 2021 Earnings Report

Organon's financial objectives were delivered, with significant steps taken to advance its vision in women’s health through business development.

Key Takeaways

Organon reported a total net revenue of $1,604 million for Q4 2021, a decrease of 1% compared to Q4 2020. Strong sales for Nexplanon and growth in biosimilars were offset by declines in Established Brands and supply sales to Merck and other third parties. Net income from continuing operations for the fourth quarter of 2021 was $202 million, or $0.79 per diluted share, compared with $376 million, or $1.48 per diluted share, in the fourth quarter of 2020.

Total net revenue was $1,604 million, a decrease of 1% compared with Q4 2020.

Women’s Health increased 6% compared with Q4 2020, driven primarily by Nexplanon, which increased 37%.

Biosimilars revenue grew 15% compared with Q4 2020, driven by continued growth in the United States for Renflexis and growth in Canada.

Established Brands decreased 2% compared to Q4 2020, primarily due to a terminated agreement in Korea for Rosuzet, loss of exclusivity for Zetia in Japan, and the negative impact of Volume Based Procurement in China.

Total Revenue

$1.6B

Previous year: $1.61B